Vicore Pharma Holding AB

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company that develops therapies for respiratory diseases in Sweden. The company's primary product is Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Buloxibutid (C21) is currently in a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and in a Phase I clinical trial for treating pulmonary hypertension. Vicore Pharma also develops Almee, an investigational medical device that has completed Phase III clinical stage. Almee is designed to address the psychological impact of living with pulmonary fibrosis. The company has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor. Additionally, Vicore Pharma has a collaboration and development agreement with Alex Therapeutics AB to develop a digital app for interstitial lung diseases, including IPF. The company was founded in 2000 and is headquartered in Stockholm, Sweden.